7000 Cardinal Place
481 articles with Cardinal Health
Telix Pharmaceuticals and Cardinal Health Enter into Distribution Agreement for Prostate Cancer Imaging
Telix Pharmaceuticals (US) Inc. today announced that it has entered into a distribution agreement with Cardinal Health (NYSE:CAH).
Emmaus, a Leader in Sickle Cell Disease Treatment, Signs Agreement with Cardinal Health to Solidify Distribution Network for Endari™ (L-glutamine oral powder)
Company Signs Fourth Major Distribution Agreement this Year
Purdue Pharma, best known for being the manufacturer of opioid drug OxyContin, is offering free doses of a treatment for opioid abuse as part of negotiations in more than 1,000 lawsuits.
The Cardinal Health (NYSE: CAH) board of directors approved a quarterly dividend of $0.4763 per share. The dividend will be payable on October 15, 2018 to shareholders of record at the close of business on October 1, 2018.
Fourth-quarter revenue increased 7 percent to $35 billion; full-year revenue increased 5 percent to $137 billion
Cardinal Health and Clayton, Dubilier & Rice Announce Partnership to Accelerate Growth of naviHealth
Investment Accelerates naviHealth's Growing Market Position in Post-Acute Care Management
FDA Advisory Committee Votes in Favor of Cardinal Health's INCRAFT® AAA Stent Graft System for the Endovascular Treatment of Infrarenal Abdominal Aortic Aneurysms
Cardinal Health announced that the U.S. Food and Drug Administration (FDA) Circulatory System Devices Panel of the Medical Devices Advisory Committee has provided a favorable recommendation on the premarket approval application for INCRAFT® AAA Stent Graft System (INCRAFT).
The medical device market was about $521.2 billion last year and is projected to hit $674.5 billion by 2022. Here’s a look at the top 10 medical device companies in the world this year.
While nearly four in 10 oncologists view precision medicine as a potential game-changer, most (57 percent) say it's too soon to predict its long-term impact, according to new research from Cardinal Health Specialty Solutions.
Sitting before a Congressional panel Tuesday the heads of pharmaceutical distributing companies said their mea culpas over not doing more to limit the flow of prescription opioids to certain parts of the country.
Cardinal Health (NYSE:CAH) today reported third-quarter fiscal year 2018 revenue of $33.6 billion, an increase of 6 percent.
Cardinal Health named Dr. Mary Ann McLane the 2018 recipient of the Cardinal Health™ urEssential Award
Cardinal Health Donates 16,000 Drug Disposal Envelopes to the National Community Pharmacists Association Foundation
Donation will help consumers dispose of unused prescription medications safely and securely
Cardinal Health plans to release third-quarter financial results for its fiscal year 2018 on May 3 prior to the opening of trading on the New York Stock Exchange. The company will webcast a discussion of these results beginning at 8:30 a.m. Eastern.
Cardinal Health Highlights Commitment To Gender Equity As Part Of Women's History Month Celebrations
With conversations around gender equity in the workplace continuing across the country, Cardinal Health emphasized the company's ongoing commitment to promoting and supporting the advancement of women in the workplace.
Cardinal Health Recommends Shareholders Reject the Below-Market Mini-Tender Offer by TRC Capital Corporation
Cardinal Health, Inc. (NYSE: CAH) today announced that it has received notice of an unsolicited "mini-tender" offer by TRC Capital Corporation (TRC Capital) to purchase up to 2 million of Cardinal Health's common shares, representing approximately 0.64 percent of Cardinal Health's common shares outstanding.
Cardinal Health Announces Closing of Cardinal Health China Distribution Business Divestiture to Shanghai Pharma
The sale includes Cardinal Health's pharmaceutical and medical products distribution business in China.
Cardinal Health plans to release second-quarter financial results for its fiscal year 2018 on February 8 prior to the opening of trading on the New York Stock Exchange.
The transaction is expected to close by the end of Cardinal Health's fiscal year, subject to closing conditions and regulatory clearances.
Physio-Control Launches Voluntary Field Action for Specific Production Lots of Infant/Child Reduced Energy Defibrillation Electrodes Produced by Cardinal Health
There is no issue with the performance or function of the defibrillation electrodes; this is limited to incorrect artwork on the defibrillation electrodes within the packaging.